Skip to main content
Terug
FOLD logo

Amicus Therapeutics, Inc.

Datakwaliteit: 100%
Overbought
FOLD
NASDAQ Healthcare Biotechnology
€ 14,43
▲ € 0,02 (0,14%)
Marktkapitalisatie: 4,53B
Dagbereik
€ 14,40 € 14,43
52-Weeksbereik
€ 5,51 € 14,43
Volume
1.953.154
50D / 200D Gem.
€ 14,33 / € 9,82
Vorige Slotkoers
€ 14,41

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -167,1 0,3
P/B 16,5 3,0
ROE % -11,6 3,7
Net Margin % -4,3 3,8
Rev Growth 5Y % 20,0 10,0
D/E 1,8 0,2

Koersdoel Analisten

Hold
€ 14,50 +0.5%
Forward K/W
47,64
Forward WPA
€ 0,30
WPA Groei (sch.)
+0,0%
Omzet Sch.
748,49M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,67
€ 1,62 – € 1,72
 1,47B 2
FY2029 € 1,36
€ 1,32 – € 1,40
 1,31B 2
FY2028 € 0,91
€ 0,75 – € 1,05
 1,09B 4

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-20 € 0,07 € 0,10 +40,0%
2025-11-04 € 0,12 € 0,17 +41,7%
2025-07-31 € 0,02 € 0,01 -50,0%
2025-05-01 € 0,08 € 0,03 -62,5%
2025-02-19 € 0,02 € 0,09 +350,0%
2024-11-06 € 0,08 € 0,10 +25,0%
2024-08-08 € 0,05 € 0,06 +9,8%
2024-05-09 -€ 0,06 -€ 0,02 +66,7%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 20,03% annually over 5 years — strong growth
Generating 29,85M in free cash flow
Capital efficient — spends only 0,52% of revenue on capex
ROIC of 3,41% — low return on invested capital
Interest coverage of 0,75× — tight debt servicing

Groei

Revenue Growth (5Y)
20,03%
Revenue (1Y)20,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-11,58%
ROIC3,41%
Net Margin-4,27%
Op. Margin5,44%

Veiligheid

Debt / Equity
1,76
Current Ratio2,84
Interest Coverage0,75

Waardering

P/E Ratio
-167,14
Forward P/E47,61
P/B Ratio16,52
EV/EBITDA139,18
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20,05% Revenue Growth (3Y) 26,02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 20,03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 634,21M Net Income (TTM) -27,11M
ROE -11,58% ROA -2,85%
Gross Margin 87,32% Operating Margin 5,44%
Net Margin -4,27% Free Cash Flow (TTM) 29,85M
ROIC 3,41% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,76 Current Ratio 2,84
Interest Coverage 0,75
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -167,14 Forward P/E 47,61
P/B Ratio 16,52 P/S Ratio 7,14
PEG Ratio 3,17 Forward PEG N/A
EV/EBITDA 139,18 Fwd EV/EBITDA N/A
Forward P/S 6,05 Fwd Earnings Yield 2,10%
FCF Yield 0,66%
Market Cap 4,53B Enterprise Value 4,80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 634,21M 528,30M 399,36M 329,23M 305,51M
Net Income -27,11M -56,11M -151,58M -236,57M -250,46M
EPS (Diluted) -0,09 -0,18 -0,51 -0,82 -0,92
Gross Profit 553,82M 475,35M 362,03M 290,63M 271,05M
Operating Income 34,49M 24,88M -77,21M -212,12M -206,43M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 949,87M 785,03M 777,88M 724,17M 905,14M
Total Liabilities 675,63M 590,99M 617,71M 601,12M 597,77M
Shareholders' Equity 274,24M 194,05M 160,17M 123,05M 307,37M
Total Debt 483,33M 443,64M 445,06M 452,12M 440,13M
Cash & Equivalents 214,01M 213,75M 246,99M 148,81M 245,20M
Current Assets 676,17M 504,74M 483,06M 423,82M 596,83M
Current Liabilities 237,83M 148,70M 167,69M 139,02M 145,98M